Evidence map›Paper›PMID 39068317›Full record

Observational studyAnnals of surgical oncology2024

Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort Study.

Charlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, Joost J M E Nuyttens, J Jan B van Lanschot, Manon C W Spaander, Roelf Valkema, Peter Paul L O Coene, Jan Willem T Dekker, Willem E Fiets and 10 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Charlène J van der ZijdenDepartment of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. c.vanderzijden@erasmusmc.nl.
Pieter C van der SluisDepartment of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Bianca MostertDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Joost J M E NuyttensDepartment of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
J Jan B van LanschotDepartment of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Manon C W SpaanderDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Roelf ValkemaDepartment of Nucleair Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Peter Paul L O CoeneDepartment of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.
Jan Willem T DekkerDepartment of Surgery, Reinier de Graaf Group, Delft, The Netherlands.
Willem E FietsDepartment of Medical Oncology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Hendrik H HartgrinkDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Wouter L HazenDepartment of Gastroenterology, Elisabeth Tweesteden Hospital, Tilburg, The Netherlands.
Ewout A KouwenhovenDepartment of Surgery, Zorggroep Twente, Almelo, The Netherlands.
Grard A P NieuwenhuijzenDepartment of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
Camiel RosmanDepartment of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
Johanna W van SandickDepartment of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Meindert N SosefDepartment of Surgery, Zuyderland Medical Center, Heerlen, The Netherlands.
Edwin S van der ZaagDepartment of Surgery, Gelre Hospital, Apeldoorn, The Netherlands.
Sjoerd M LagardeDepartment of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Bas P L WijnhovenDepartment of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite trimodality treatment, 10% to 20% of patients with esophageal cancer experience interval metastases after surgery. Restaging may identify patients who should not proceed to surgery, as well as a subgroup with limited metastases for whom long-term disease-control can be obtained. This study aimed to determine the proportion of patients with interval metastases after neoadjuvant chemoradiotherapy (nCRT) and to evaluate treatment and survival.

methodsPatients who had cT2-4aN0-3M0 esophageal cancer treated with nCRT were identified from a trial database. Metastases detected up to 14 weeks after nCRT on

resultsBetween 2013 and 2021, 973 patients received nCRT, and 10.3% had interval metastases. Of 100 patients, 30 (30%) had oligometastases, located mostly in non-regional lymph nodes (33.3%) or bones (26.7%). The median OS of this group was 13.8 months (95% confidence interval [CI] 9.2-27.1 months). Of 30 patients, 12 (40%) with oligometastases underwent potentially curative treatment, with a median OS of 22.8 months (95% CI 10.4-NA). The patients with non-oligometastases underwent mostly systemic therapy or BSC and had a median OS of 9 months (95% CI 7.4-10.9 months).

conclusionsInterval metastases were detected in about 10% of patients after nCRT, underscoring the importance of re-staging with

Indexed as

Esophageal NeoplasmsNeoadjuvant TherapyPositron Emission Tomography Computed TomographyAgedCarcinoma, Squamous CellChemoradiotherapyChemoradiotherapy, AdjuvantEsophagectomyFemaleFluorodeoxyglucose F18Follow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedPrognosisFluorodeoxyglucose F18ChemoradiotherapyEsophageal cancerEsophagogastric junction cancerInterval metastasesPalliative therapy

Identifiers

PMID39068317
PMCPMC11467105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.